Can Aspirin Cause or Worsen Acid Reflux?

Aspirin can both trigger and worsen acid reflux. Roughly one in six people taking even low-dose aspirin reports upper gastrointestinal symptoms, and the majority of those symptoms involve heartburn or acid regurgitation. The mechanism goes beyond simple stomach irritation: aspirin changes how vulnerable the esophageal lining is to acid damage. Whether this matters to you depends on your dose, your anatomy, and a few risk factors worth knowing about.

How Aspirin Damages the Digestive Tract

Aspirin belongs to a class of drugs that work by blocking an enzyme involved in inflammation. A side effect of that same block is a drop in the protective substances that line the stomach and esophagus. These substances, called prostaglandins, help maintain a mucus barrier that shields the tissue from its own acid. When aspirin suppresses them, the lining becomes more exposed. Research has shown that aspirin makes the esophageal lining more permeable to both acid and pepsin, the digestive enzyme in stomach juice, and that adding prostaglandin therapy before aspirin exposure reduces that damage by more than 40 percent.¹

There is also a direct contact effect. If an aspirin tablet lodges in the esophagus or dissolves slowly on its way down, it can burn the tissue on the spot. Case reports have documented aspirin and similar anti-inflammatory drugs causing full-blown esophageal inflammation, sometimes severe enough to produce narrowing of the esophagus, bleeding, or even perforation.² This kind of injury is more likely if you take aspirin without enough water, lie down shortly after swallowing it, or have any structural narrowing in the esophagus that slows a pill’s transit.

How Common Are Reflux Symptoms on Aspirin

The short answer is common enough to affect daily life for a meaningful number of people. A large survey of low-dose aspirin users, known as the UGLA survey, found that about 15 percent reported upper gastrointestinal symptoms. Among those who had symptoms, 70 percent described gastroesophageal reflux specifically, meaning heartburn, regurgitation, or both. Broader estimates put reflux and related symptoms at up to 15 to 20 percent of all low-dose aspirin users.³ Those numbers matter because many people take low-dose aspirin for years, sometimes decades, for cardiovascular protection.

Compliance is the practical fallout. The same survey data showed that reflux symptoms led about 12 percent of aspirin users to take the drug less consistently or stop it altogether.³ For someone prescribed aspirin after a heart attack or stent placement, that interruption can carry serious cardiovascular risk. The reflux problem is not just discomfort; it creates a genuine tug of war between the heart and the gut.

Who Is Most Vulnerable

Not everyone who takes aspirin develops reflux or stomach damage. Several factors stack the odds against you, and they interact with each other in ways that make individual risk hard to predict from any single characteristic.

Prior ulcer history: If you have had a peptic ulcer before, aspirin is substantially more likely to cause new mucosal injury.
Dual antiplatelet therapy: Taking aspirin alongside another blood thinner like clopidogrel amplifies gut damage beyond what aspirin does alone.
Male sex: Men show a higher rate of aspirin-induced gastric mucosal injury in clinical studies.
H. pylori infection: This common stomach bacterium independently damages the lining, and its presence alongside aspirin use increases the likelihood of ulcers and bleeding.

A study examining both clinical and genetic risk factors confirmed that each of these characteristics independently raises the chance of mucosal injury in aspirin users.⁴ The H. pylori question has been debated extensively. Various gastroenterology consensus groups have recommended testing for H. pylori and treating the infection in aspirin users who have a history of ulcers or ulcer bleeding, though the broader benefit of routine testing in all aspirin users remains controversial.⁵ Eradication therapy in patients with a peptic ulcer history does appear to reduce recurrence, which is why many clinicians order the test when starting long-term aspirin in someone with past ulcer disease.⁶

Does Enteric Coating Make a Difference

Enteric-coated aspirin is designed to pass through the stomach intact and dissolve in the small intestine instead. The logic is simple: if the tablet does not dissolve in the stomach, it cannot directly irritate the stomach lining. And the evidence suggests that the coating works for that narrow purpose. A controlled study comparing enteric-coated aspirin with plain aspirin found that the coated form produced mucosal lesion scores no different from placebo on the first day. After a week of daily dosing, enteric-coated aspirin still caused significantly fewer gastroduodenal lesions than plain aspirin.⁷

The catch is that most of aspirin’s gut damage is not just local contact irritation. The systemic effect, the suppression of prostaglandins throughout the body once aspirin enters the bloodstream, happens regardless of where the tablet dissolves. Enteric coating reduces the direct chemical burn on the stomach, which is a real benefit. But it does not eliminate the broader drop in mucosal protection or the increased esophageal permeability that comes from prostaglandin suppression. If you already have reflux, switching to enteric-coated aspirin may reduce some stomach symptoms without fully addressing the esophageal problem.

Using Acid-Suppressing Drugs Alongside Aspirin

For people who need aspirin and cannot tolerate the gut symptoms, proton pump inhibitors are the standard co-therapy. These drugs reduce the amount of acid the stomach produces, which limits the damage that acid can do to already-weakened tissue. The evidence for this approach is strong. A meta-analysis pooling data from multiple trials found that PPIs cut the risk of aspirin-associated upper gastrointestinal ulcers by about 84 percent and reduced bleeding events substantially as well.⁸ PPIs also outperformed another class of acid-reducing drugs, H2 blockers, in head-to-head comparisons for both ulcer prevention and bleeding prevention in aspirin users.⁸

The esophageal side of the equation matters too. In a large randomized trial of older adults taking daily low-dose aspirin, those given esomeprazole (a PPI) had an erosive esophagitis rate of about 4 percent at six months, compared with roughly 18 percent in the placebo group. The PPI group was also more likely to see resolution of heartburn, acid regurgitation, and upper abdominal pain.⁹ This is important because it demonstrates that the reflux symptoms linked to aspirin are not just a nuisance. Without treatment, a significant fraction of long-term aspirin users develop visible esophageal erosion on endoscopy.

The case for adding a PPI is clearest in patients who carry additional risk factors: older age, prior ulcers, concurrent use of other blood thinners, or existing reflux disease. For people who take aspirin to prevent cardiovascular events, stopping aspirin because of gut symptoms can itself be dangerous. Co-therapy with a PPI keeps both the heart protection and the digestive tract intact.¹⁰ Long-term PPI use carries its own concerns, including possible effects on nutrient absorption and bone density, so the decision is usually a conversation with a doctor rather than a reflex prescription.

Practical Steps to Reduce Symptoms

If you need to keep taking aspirin and you are dealing with reflux symptoms, a few straightforward measures can help beyond medication changes.

Take aspirin with a full glass of water and remain upright for at least 30 minutes afterward. This sounds simple, but many cases of pill-induced esophagitis happen because the tablet sticks somewhere in the esophagus on the way down, especially in people who swallow it dry or with a small sip right before bed. Taking it with food, particularly a meal that includes some starch or bread, can also buffer the direct irritant effect on the stomach.

If your reflux symptoms started or worsened around the time you began aspirin, mention that to your prescribing doctor. There is a meaningful difference between reflux that predated aspirin and reflux that aspirin seems to be causing. In the first case, the issue is that aspirin is aggravating an existing weakness in the barrier between the stomach and esophagus. In the second, aspirin itself may be the primary driver, and adjusting the formulation, timing, or adding acid suppression may resolve it entirely. Either way, do not stop aspirin on your own if it was prescribed for cardiovascular reasons. The risk of a cardiac event after abruptly discontinuing aspirin is real and well documented.

The Surprising Barrett’s Esophagus Connection

Here is where the story takes a counterintuitive turn. Barrett’s esophagus is a condition in which the lining of the lower esophagus changes in response to chronic acid exposure, and it is considered a precursor to a type of esophageal cancer. You might assume that a drug linked to more reflux would also increase the risk of Barrett’s. The opposite appears to be true. A multivariate analysis found that current aspirin users had a significantly lower risk of developing Barrett’s esophagus compared with non-users, with an odds ratio of 0.56. That finding held even when the analysis was limited to patients who had endoscopies specifically because of reflux symptoms.¹¹

The likely explanation involves aspirin’s anti-inflammatory effects working at a cellular level to discourage the kind of tissue transformation that leads to Barrett’s. The same prostaglandin suppression that weakens the mucosal barrier also inhibits inflammatory pathways involved in abnormal cell growth. So aspirin damages the surface while potentially protecting against deeper, longer-term changes. This dual nature is one of the most studied paradoxes in gastroenterology, and it has implications for whether aspirin might be useful in cancer prevention, a question still being explored in clinical trials.

Genetic Factors That Affect Your Gut’s Response to Aspirin

Why does one person take low-dose aspirin for a decade without a single bout of heartburn, while another develops stomach erosions within weeks? Part of the answer is genetic. The enzyme that aspirin targets varies slightly from person to person due to inherited differences in the gene that codes for it. Certain genetic variants in this enzyme have been linked to lower prostaglandin production and increased sensitivity to aspirin’s effects, though the statistical evidence connecting these specific variants to bleeding ulcers has not always reached significance.¹²

Other genetic markers have shown stronger associations. A study of aspirin users identified two specific gene variants, one in an inflammatory signaling gene and another in a gene related to mucosal defense, that were associated with higher rates of gastric mucosal injury.⁴ Genetic testing for aspirin sensitivity is not yet routine clinical practice, but the research hints at a future where the decision to add a PPI might be guided by a simple blood or saliva test rather than waiting for symptoms to appear. For now, the practical takeaway is that if aspirin gives you gut trouble while the person next to you tolerates it effortlessly, the difference is not imaginary and is not entirely explained by diet, stress, or the brand you bought. Biology plays a real part.

Choosing an Antiplatelet Agent When Gut Risk Is High

For some patients, the reflux and bleeding risk from aspirin is severe enough to warrant considering an alternative antiplatelet drug. Clopidogrel is the most common substitute. It works through a different mechanism and does not directly suppress prostaglandins, which means it avoids the specific mucosal damage pathway aspirin triggers. Gastrointestinal bleeding is a recognized complication of all antiplatelet agents, but the profile differs, and the choice between aspirin and clopidogrel involves weighing the cardiovascular indication against the individual patient’s gastrointestinal risk.¹³

Clopidogrel is not without its own gut risks, and it interacts with PPIs in a way that has generated years of debate about whether the two can be safely used together. A meta-analysis showed that PPIs were able to prevent aspirin-associated gastrointestinal bleeding even in patients on dual antiplatelet therapy without increasing the risk of heart attacks or strokes.⁸ That finding eased some of the concern, though many cardiologists and gastroenterologists still evaluate the combination on a case-by-case basis. The decision to switch from aspirin is not one to make based on reflux alone. It involves weighing the strength of the cardiovascular indication, the severity of the GI symptoms, and whether simpler interventions like adding a PPI have already been tried and failed.

1
PubMed. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin
2
Journal of Gastroenterology Research. Pill-Induced Esophagitis with Mucosal Dissection: A Case Report
3
Best Practice & Research Clinical Gastroenterology. Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract
4
PubMed Central. Study of Clinical and Genetic Risk Factors for Aspirin-induced Gastric Mucosal Injury
5
PubMed. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice
6
PubMed. Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between H. pylori Infection and Low-Dose Aspirin Use
7
PubMed. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions
8
PubMed Central. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries
9
PubMed Central. Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
10
PubMed. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett’s esophagus
11
PubMed Central. Aspirin Protects Against Barrett’s Esophagus in a Multivariate Logistic Regression Analysis
12
PubMed. Aspirin-induced peptic ulcer and genetic polymorphisms
13
PubMed Central. Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed